Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 2194-2202

  Simmonds, Rachel E ^a   Lali, Ferdinand V ^b   Smallie, Tim ^a   Small, Pamela L C ^a   Foxwell, Brian M ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYCOLACTONE; RAPAMYCIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; LIPOPOLYSACCHARIDE;

ARTICLE; BACTERIAL VIRULENCE; BURULI ULCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; MONOCYTE; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BIOSYNTHESIS; GENETIC TRANSCRIPTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN SYNTHESIS; WESTERN BLOTTING;

BACTERIAL TOXINS; BLOTTING, WESTERN; BURULI ULCER; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; LIPOPOLYSACCHARIDES; MONOCYTES; PROTEIN BIOSYNTHESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSCRIPTION, GENETIC;

EID: 61449255984     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802294     Document Type: Article

References (41)

1. Wansbrough-Jones, M., and R. Phillips. 2006. Buruli ulcer: emerging from obscurity. Lancet 367: 1849-1858.
2. 2008. Buruli ulcer: progress report, 2004-2008. Wkly. Epidemiol. Rec. 83: 145-154.
3. George, K. M., L. P. Barker, D. M. Welty, and P. L. Small. 1998. Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect. Immun. 66: 587-593.
4. George, K. M., D. Chatterjee, G. Gunawardana, D. Welty, J. Hayman, R. Lee, and P. L. Small. 1999. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
5. George, K. M., L. Pascopella, D. M. Welty, and P. L. Small. 2000. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect. Immun. 68: 877-883.
6. Stinear, T. P., A. Mve-Obiang, P. L. Small, W. Frigui, M. J. Pryor, R. Brosch, G. A. Jenkin, P. D. Johnson, J. K. Davies, R. E. Lee, et al. 2004. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc. Natl. Acad. Sci. USA 101: 1345-1349.
7. Adusumilli, S., A. Mve-Obiang, T. Sparer, W. Meyers, J. Hayman, and P. L. Small. 2005. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol. 7: 1295-1304.
8. Hong, H., C. Demangel, S. J. Pidot, P. F. Leadlay, and T. Stinear. 2008. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat. Prod. Rep. 25: 447-454.
9. Coutanceau, E., L. Marsollier, R. Brosch, E. Perret, P. Goossens, M. Tanguy, S. T. Cole, P. L. Small, and C. Demangel. 2005. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol. 7: 1187-1196.
10. Torrado, E., A. G. Fraga, A. G. Castro, P. Stragier, W. M. Meyers, F. Portaels, M. T. Silva, and J. Pedrosa. 2007. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect. Immun. 75: 977-987.
11. Pahlevan, A. A., D. J. Wright, C. Andrews, K. M. George, P. L. Small, and B. M. Foxwell. 1999. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-κB function. J. Immunol. 163: 3928-3935.
12. Torrado, E., S. Adusumilli, A. G. Fraga, P. L. Small, A. G. Castro, and J. Pedrosa. 2007. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect. Immun. 75: 3979-3988.
13. Coutanceau, E., J. Decalf, A. Martino, A. Babon, N. Winter, S. T. Cole, M. L. Albert, and C. Demangel. 2007. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J. Exp. Med. 204: 1395-1403.
14. Hayman, J. 1993. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J. Clin. Pathol. 46: 5-9.
15. Kiszewski, A. E., E. Becerril, L. D. Aguilar, I. T. Kader, W. Myers, F. Portaels, and R. Hernandez Pando. 2006. The local immune response in ulcerative lesions of Buruli disease. Clin. Exp. Immunol. 143: 445-451.
16. Pandey, S., and D. K. Agrawal. 2006. Immunobiology of Toll-like receptors: emerging trends. Immunol. Cell Biol. 84: 333-341.
17. Levin, J., and F. B. Bang. 1964. The role of endotoxin in the extracellular coagulation of limulus blood. Bull. Johns Hopkins Hosp. 115: 265-274.
18. Gunawardana, G., D. Chatterjee, K. M. George, P. Brennan, D. Whittern, and P. L. C. Small. 1999. Characterization of novel macrolide toxins, mycolactones A and B, from a human pathogen, Mycobacterium ulcerans. J. Am. Chem. Soc. 121: 6092-6093.
19. Foxwell, B., K. Browne, J. Bondeson, C. Clarke, R. de Martin, F. Brennan, and M. Feldmann. 1998. Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent. Proc. Natl. Acad. Sci. USA 95: 8211-8215.
20. Buchan, G., K. Barrett, M. Turner, D. Chantry, R. N. Maini, and M. Feldmann. 1988. Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin. Exp. Immunol. 73: 449-455.
21. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
22. Saklatvala, J., L. Rawlinson, R. J. Waller, S. Sarsfield, J. C. Lee, L. F. Morton, M. J. Barnes, and R. W. Farndale. 1996. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J. Biol. Chem. 271: 6586-6589.
23. Denys, A., I. A. Udalova, C. Smith, L. M. Williams, C. J. Ciesielski, J. Campbell, C. Andrews, D. Kwaitkowski, and B. M. Foxwell. 2002. Evidence for a dual mechanism for IL-10 suppression of TNF-α production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-κB in primary human macrophages. J. Immunol. 168: 4837-4845.
24. T) method. Methods 25: 402-408.
25. Crawley, J. B., L. M. Williams, T. Mander, F. M. Brennan, and B. M. Foxwell. 1996. Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J. Biol. Chem. 271: 16357-16362.
26. Jarrous, N., and R. Kaempfer. 1994. Induction of human interleukin-1 gene expression by retinoic acid and its regulation at processing of precursor transcripts. J. Biol. Chem. 269: 23141-23149.
27. Yamamoto, M., S. Yamazaki, S. Uematsu, S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Kuwata, O. Takeuchi, K. Takeshige, et al. 2004. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IκBζ. Nature 430: 218-222.
28. Yamasaki, S., and P. Anderson. 2008. Reprogramming mRNA translation during stress. Curr. Opin. Cell Biol. 20: 222-226.
29. Simmonds, R. E., and B. M. Foxwell. 2008. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology 47: 584-590.
30. Lundberg, A. M., S. K. Drexler, C. Monaco, L. M. Williams, S. M. Sacre, M. Feldmann, and B. M. Foxwell. 2007. Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood 110: 3245-3252.
31. Sacre, S. M., A. M. Lundberg, E. Andreakos, C. Taylor, M. Feldmann, and B. M. Foxwell. 2007. Selective use of TRAM in lipopolysaccharide (LPS) and lipoteichoic acid (LTA) induced NF-κB activation and cytokine production in primary human cells: TRAM is an adaptor for LPS and LTA signaling. J. Immunol. 178: 2148-2154.
32. Peduzzi, E., C. Groeper, D. Schutte, P. Zajac, S. Rondini, E. Mensah-Quainoo, G. C. Spagnoli, G. Pluschke, and C. A. Daubenberger. 2007. Local activation of the innate immune system in Buruli ulcer lesions. J. Invest. Dermatol. 127: 638-645.
33. Prevot, G., E. Bourreau, H. Pascalis, R. Pradinaud, A. Tanghe, K. Huygen, and P. Launois. 2004. Differential production of systemic and intralesional γ interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect. Immun. 72: 958-965.
34. Phillips, R., C. Horsfield, J. Mangan, K. Laing, S. Etuaful, P. Awuah, K. Nyarko, F. Osei-Sarpong, P. Butcher, S. Lucas, and M. Wansbrough-Jones. 2006. Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. Infect. Immun. 74: 2917-2924.
35. Gooding, T. M., P. D. Johnson, D. E. Campbell, J. A. Hayman, E. L. Hartland, A. S. Kemp, and R. M. Robins-Browne. 2001. Immune response to infection with Mycobacterium ulcerans. Infect. Immun. 69: 1704-1707.
36. Gooding, T. M., P. D. Johnson, M. Smith, A. S. Kemp, and R. M. Robins-Browne. 2002. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect. Immun. 70: 5562-5567.
37. Westenbrink, B. D., Y. Stienstra, M. G. Huitema, W. A. Thompson, E. O. Klutse, E. O. Ampadu, H. M. Boezen, P. C. Limburg, and T. S. van der Werf. 2005. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin. Diagn. Lab. Immunol. 12: 125-129.
38. Phillips, R., C. Horsfield, S. Kuijper, S. F. Sarfo, J. Obeng-Baah, S. Etuaful, B. Nyamekye, P. Awuah, K. M. Nyarko, F. Osei-Sarpong, et al. 2006. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin. Vaccine Immunol. 13: 253-257.
39. Yeboah-Manu, D., E. Peduzzi, E. Mensah-Quainoo, A. Asante-Poku, D. Ofori-Adjei, G. Pluschke, and C. A. Daubenberger. 2006. Systemic suppression of interferon-γ responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J. Leukocyte Biol. 79: 1150-1156.
40. Schipper, H. S., B. Rutgers, M. G. Huitema, S. N. Etuaful, B. D. Westenbrink, P. C. Limburg, W. Timens, and T. S. van der Werf. 2007. Systemic and local interferon-γ production following Mycobacterium ulcerans infection. Clin. Exp. Immunol. 150: 451-459.
41. Hong, H., E. Coutanceau, M. Leclerc, L. Caleechurn, P. F. Leadlay, C. Demangel. 2008. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl. Trop. Dis. 2: e325.